Atai Life Sciences NV (ATAI) Company Overview

As psychedelics stocks trade higher following the release of positive data for GH Research's 5-MeO-DMT drug for treatment-resistant depression, analysts at Jefferies believe Beckley Psytech's intranasal 5-MeO-DMT candidate BPL-003 could have an even better value proposition. This could have a positive readthrough for atai Life Sciences (NASDAQ:ATAI, ETR:9VC), an investor in Beckley.

Positive data from Irish biotechnology firm GH Research's Phase 2 trial of GH001, an inhalation formulation of synthetic mebufotenin (5-MeO-DMT), in treatment-resistant depression bodes well for atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' own psychedelic, analysts at Jefferies believe. Jefferies repeated its ‘Buy' rating on atai and awarded it a $5 price target.

Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients, showing a 50% abstinence in patients over a 12-week period. Release of results from the phase 2b study using BPL-003 for treatment-resistant depression expected in mid-2025. The global treatment-resistant depression treatment market is projected to reach $4.06 billion by 2030.

atai Life Sciences could create value in the near-term with the release of key Phase 2 and 3 datasets for psychedelic drug candidates over the next 12 to 18 months, analysts at Jefferies believe. “Seeing positive data could strengthen the notion psychedelics have an important role for hard-to-treat $1 billion-plus central nervous systems disorders, as well as reassure investors the FDA's rejection of MDMA in 2024 was more of an idiosyncrasy,” analysts wrote in a note to clients.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced positive topline results from Beckley Psytech's Phase 2a study of BPL-003 (intranasal 5-MeO-DMT benzoate) in alcohol use disorder. The company said a single dose of BPL-003 in combination with relapse prevention therapy produced “meaningful and sustained reductions” in alcohol use, with the mean number of alcohol units consumed per day decreasing from 9.3 units to 2.2 units.

- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer - Kevin Craig, M.D. promoted to Chief Medical Officer - Glenn Short, Ph.D. promoted to Chief Scientific Officer - Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares should move higher on a slew of Phase 2 and 3 data readouts in 2025 from across its pipeline of innovative psychedelic therapies, analysts at Jefferies. Following the release of atai's third quarter results earlier this week, the analysts repeated their ‘Buy' rating on the stock and awarded it a $5 price target, implying upside of 242% from its share price at the time of writing.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC), a biopharmaceutical company targeting mental health disorders, advanced its pipeline of innovative therapies during the third quarter of 2024. Notably, the US Food and Drug Administration approved an investigational new drug application for for VLS-01, atai's buccal film formulation of DMT.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' chief scientific officer Dr Srinivas Rao joined Proactive to discuss the company's latest clinical trial results. Dr Rao detailed the positive outcomes from the Phase 1B trial of the VLS-01 (oral DMT) program, emphasizing the drug's excellent tolerability and potential as a best-in-class treatment option.